Association between statin-associated myopathy and skeletal muscle damage

Mohaupt, Markus G.; Karas, Richard H.; Babiychuk, Eduard B.; Sanchez-Freire, Verónica; Monastyrskaya, Katia; Iyer, Lakshmanan; Hoppeler, Hans; Breil, Fabio; Draeger, Annette
July 2009
CMAJ: Canadian Medical Association Journal;7/7/2009, Vol. 181 Issue 1/2, pE11
Academic Journal
Background: Many patients taking statins often complain of muscle pain and weakness. The extent to which muscle pain reflects muscle injury is unknown. Methods: We obtained biopsy samples from the vastus lateralis muscle of 83 patients. Of the 44 patients with clinically diagnosed statin-associated myopathy, 29 were currently taking a statin, and 15 had discontinued statin therapy before the biopsy (minimal duration of discontinuation 3 weeks). We also included 19 patients who were taking statins and had no myopathy, and 20 patients who had never taken statins and had no myopathy. We classified the muscles as injured if 2% or more of the muscle fibres in a biopsy sample showed damage. Using reverse transcriptase polymerase chain reaction, we evaluated the expression levels of candidate genes potentially related to myocyte injury. Results: Muscle injury was observed in 25 (of 44) patients with myopathy and in 1 patient without myopathy. Only 1 patient with structural injury had a circulating level of creatine phosphokinase that was elevated more than 1950 U/L (10× the upper limit of normal). Expression of ryanodine receptor 3 was significantly upregulated in patients with biopsy evidence of structural damage (1.7, standard error of the mean 0.3). Interpretation: Persistent myopathy in patients taking statins reflects structural muscle damage. A lack of elevated levels of circulating creatine phosphokinase does not rule out structural muscle injury. Upregulation of the expression of ryanodine receptor 3 is suggestive of an intracellular calcium leak.


Related Articles

  • Exercise-induced Myalgia may Limit the Cardiovascular Benefits of Statins. Opie, Lionel H. // Cardiovascular Drugs & Therapy;Dec2013, Vol. 27 Issue 6, p569 

    The positive health benefits of statins extend beyond the cardiovascular and include increased flow mediated dilation, decreased atrial fibrillation, modest antihypertensive effects and reduced risks of malignancies. Prominent among the statin side-effects are myalgia and muscular weakness,...

  • Gender Effects on Statin-Associated Muscular Adverse Events: An Analysis of the FDA AERS Database. Hiroyuki Murakami; Toshiyuki Sakaeda; Kaori Kadoyama; Yasushi Okuno // Pharmacology & Pharmacy;Jun2013, Vol. 4 Issue 3, p340 

    Objective: The reports submitted to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from 1997 to 2011 were reviewed to assess the gender effects on muscular adverse events induced by the administration of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase...

  • Statin induced myopathy. Sathasivam, Sivakumar; Lecky, Bryan // BMJ: British Medical Journal (International Edition);11/15/2008, Vol. 337 Issue 7679, p1159 

    The article discusses statin induced myopathy. The author explains that the term myopathy is used for the entire spectrum of muscle related adverse events including myalgia, myositis, and rhabdomyolysis. Clinical features including muscle tenderness, muscle pain, and tendon pain are listed. The...

  • An Unusual Case of Statin-Induced Myopathy: Anti-HMGCoA Necrotizing Autoimmune Myopathy. Nichols, Laura; Pfeifer, Kurt; Mammen, Andrew; Shahnoor, Nazima; Konersman, Chamindra; Mammen, Andrew L; Konersman, Chamindra G // JGIM: Journal of General Internal Medicine;Dec2015, Vol. 30 Issue 12, p1879 

    Statins are some of the most widely prescribed medications, and though generally well tolerated, can lead to a self-limited myopathy in a minority of patients. Recently, these medications have been associated with a necrotizing autoimmune myopathy (NAM). Statin-associated NAM is characterized by...

  • Statin Therapy for Primary Prevention of Cardiovascular Disease. Taylor, Fiona C.; Huffman, Mark; Ebrahim, Shah // JAMA: Journal of the American Medical Association;12/11/2013, Vol. 310 Issue 22, p2451 

    The article focuses on the use of statins for the primary prevention of cardiovascular disease. Several trials showed the effectiveness of statins in reducing all-cause mortality, major vascular events and coronary revascularization compared with placebo. They also identified potential side...

  • Atorvastatin.  // Reactions Weekly;4/24/2010, Issue 1298, p11 

    The article describes the case of an 80-year old woman who developed myopathy while undergoing treatment with atorvastatin.

  • HMG-CoA reductase inhibitors.  // Reactions Weekly;8/14/2010, Issue 1314, p22 

    The article describes the case of a women who acquired myalgia while undergoing treatment with HMG-CoA reductase inhibitors.

  • High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults. Traustadóttir, Tinna; Stock, Anthoney; Harman, S. // Age;2008, Vol. 30 Issue 4, p283 

    3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are lipid-lowering agents widely employed for atherosclerosis prevention. HMG-CoA reductase blockade reduces skeletal muscle coenzyme Q10 (CoQ10) levels and mitochondrial respiratory chain activities and may produce...

  • Rosuvastatin.  // Reactions Weekly;3/13/2010, Issue 1292, p32 

    The article describes the case of a 57-year-old man who developed thrombocytopenic purpura while receiving treatment with rosuvastatin for hypercholesterolemia.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics